CLINICAL TRIALS PROFILE FOR LITHIUM CARBONATE
✉ Email this page to a colleague
All Clinical Trials for Lithium Carbonate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000369 ↗ | Maintenance Therapies in Bipolar Disorders | Completed | University of Pittsburgh | Phase 3 | 1997-06-01 | The purpose of this study is to see if adding a regimen of individualized psychotherapy can help bipolar I patients who are on lithium. While having a manic or depressed episode patients will be assigned randomly (like tossing a coin) to receive appropriate medication either with or without additional individual psychotherapy. If a patient responds well, he/she will again be assigned randomly to receive further preventative treatment in which medication will be managed either with continued medication clinic visits alone or with additional individual psychotherapy (the patient may not receive the same additional treatment this time). Patient response to treatment will be evaluated throughout the study. If manic/depressive symptoms return at any point during the study, the patient will be treated with appropriate medication and will continue the study. An individual may be eligible for this study if he/she: Has Bipolar I disorder, is experiencing a manic or depressed episode at the time of study entry, and is at least 18 years old. |
| NCT00000439 ↗ | Drug Treatment for Alcoholics With Bipolar Disorder | Completed | University of Pittsburgh | Phase 2 | 2000-10-01 | The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder. |
| NCT00000439 ↗ | Drug Treatment for Alcoholics With Bipolar Disorder | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2000-10-01 | The purpose of this study is to test the effectiveness of sodium valproate (Depacon) in treating individuals with alcohol dependence and comorbid bipolar disorder. |
| NCT00005015 ↗ | Treatment of Depression in Youth With Bipolar Disorders | Terminated | National Institute of Mental Health (NIMH) | Phase 3 | 1969-12-31 | THIS STUDY HAS BEEN DISCONTINUED. The study is designed to evaluate the safety and efficacy of fluoxetine for treating children and adolescents with Bipolar Disorder who are experiencing an episode of major depression while being treated with a mood stabilizer. The study involves a 2-week assessment period. Patients who are on stable, therapeutic doses of lithium or valproate and continue to have depression will be randomized to a 12-week treatment of fluoxetine or placebo. Those who respond favorably to treatment will be followed openly for an 18-week continuation phase. |
| NCT00057681 ↗ | Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents | Completed | National Institute of Mental Health (NIMH) | Phase 3 | 2003-02-01 | This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania. |
| NCT00057681 ↗ | Study of Outcome and Safety of Lithium, Divalproex and Risperidone for Mania in Children and Adolescents | Completed | Washington University School of Medicine | Phase 3 | 2003-02-01 | This study will evaluate the effectiveness of the medications, lithium (Eskalith®), valproate (Depakote®), and risperidone (Risperdal®) in treating children and adolescents with bipolar disorder or symptoms of mania. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Lithium Carbonate
Condition Name
Clinical Trial Locations for Lithium Carbonate
Trials by Country
Clinical Trial Progress for Lithium Carbonate
Clinical Trial Phase
Clinical Trial Sponsors for Lithium Carbonate
Sponsor Name
